Advanced Particle Engineering for Respiratory Drug Delivery Applications

用于呼吸药物输送应用的先进粒子工程

• 批准号: 543336-2019
• 负责人: Vehring, Reinhard
• 金额: $ 14.21万
• 依托单位: University of Alberta
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=699585
• 关键词: Advanced; Particle; Engineering; Respiratory; Drug

This proposal addresses technology development in the area of pressurized metered dose inhalers for respiratory drug delivery. The state of the art in this field is highly developed, but connected to traditional propellants which contribute to global warming because they are very effective greenhouse gases. In response, the industry partner is preparing for a switch to alternative, less harmful propellants. The proposed work will contribute to the selection of an appropriate substitute propellant and will provide the theoretical basis for predictions of product performance in the alternate format. Furthermore, the impact of this switch on the stability of suspension based metered dose inhalers will be studied both theoretically and experimentally. Lastly, new microparticle types that are compatible with the new propellants and can be used for the formulation of biologics will be designed. The work will employ an engineering approach based on mechanistic understanding of particle propellant interactions and particle formation mechanisms. Effects that cannot currently be modeled theoretically will be studies in idealized experimental surrogate systems. The industry partner will then incorporate the results directly into ongoing development projects. It is expected that this work will lead to a reduction in the emission of greenhouse gases during production and use of such products. Furthermore, it is expected that the range of applicability of the suspension based metered dose inhaler platform can be extended to biologics, which have shown great potential in the treatment of a variety of respiratory diseases, including asthma and chronic obstructive pulmonary disease. Hence, this project will likely lead to substantial improvements in environmental protection globally and in more efficacious therapeutics for conditions that place a large burden on the Canadian health care system.

该建议介绍了加压计量剂量吸入器的技术开发，用于输送呼吸药物。该领域的最新技术是高度发达的，但与传统推进剂有关，这些推进剂有助于全球变暖，因为它们是非常有效的温室气体。作为回应，行业合作伙伴正在准备改用替代性，不太有害的推进剂。拟议的工作将有助于选择适当的替代推进剂，并为替代格式预测产品性能的理论基础。此外，将在理论上和实验中研究这种转换对悬浮剂量剂量吸入器稳定性的影响。最后，将设计与新推进剂兼容的新微粒类型，可用于制造生物制剂。 这项工作将基于对颗粒推进剂相互作用和粒子形成机制的机械理解采用工程方法。从理论上讲，目前无法对当前无法对其进行建模的效果将是在理想化的实验替代系统中进行的研究。然后，行业合作伙伴将将结果直接纳入正在进行的开发项目中。 预计这项工作将导致生产和使用此类产品期间温室气体排放的减少。此外，可以预期，基于悬浮液的计量剂量吸入器平台的适用性范围可以扩展到生物制剂，这在治疗各种呼吸道疾病（包括哮喘和慢性阻塞性肺部疾病）方面表现出巨大的潜力。因此，该项目可能会导致全球环境保护以及对加拿大医疗保健系统造成巨大负担的疾病的更有效的治疗剂的实质性改善。